Dr. Lehman received his Ph.D. from the University of Southern California, Los Angeles, California in 1998. He completed his post-doctoral studies and fellowship in neuropathology at Stanford University, Palo Alto, California, in 2002 and was subsequently on the faculty at Stanford and then Wayne State University, Detroit, Michigan. At Stanford he studied cell cycle alteration in cancer cells through misregulation of the ubiquitin proteasome system. Beginning in 2012 he was as an experimental neuropathologist and Director of Neuropathology at Ohio State University.  He joined the University of Louisville Department of Pathology on August 21^st. His lab’s interests are on biological and molecular mechanisms of oncogenic drivers of CNS neoplasms, especially in regard to their potential as new therapeutic targets. Their current research focus is Aurora A kinase inhibition as a treatment for glioblastoma. He has also been a contributing member of The Cancer Genome Atlas Research Network Glioma Working Group. His additional interests are in mechanisms of neurodegeneration